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The search for robust, reliable and valid biomarkers of 
the ageing process is a key goal for gerontological 
science. Such tools should enable the quantification of 
individual differences in underlying biological ageing. 
This could have great utility for mapping personalised 
ageing trajectories, for predicting risk of future age-
related deterioration and disease and for evaluating 
potential treatments aimed at improving healthspan or 
even slowing ageing itself. Given the multi-faceted 
nature of biological ageing, numerous potential 
candidate biomarkers have been proposed. These can be 
anthropometric, physiological or blood-based; indexing 
immune function, epigenetic signatures, gene 
expression profiles, physical capacity or body 
composition [1]. To improve on individual predictors of 
biological age, panels combining multiple markers have 
also been proposed [2]. While many of these 
approaches are highly promising, the results have yet to 
be translated into clinical practice. 
The criteria most commonly used for assessing the 
appropriateness of ageing biomarkers is how strongly 
they correlate with chronological age in healthy people. 
In addition, thanks to the increasing use of machine 
learning, the accuracy with which chronological age can 
be predicted using multivariate biological data is also a 
useful indicator of potential biomarker value. Aligned 
with this, an independent line of research has emerged 
from the field of neuroscience. Using neuroimaging 
data, principally magnetic resonance imaging (MRI) 
brain scans, chronological age can be predicted 
accurately in a machine-learning framework [3]. This 
neuroimaging-derived brain-age model is based on data 
from over 2000 healthy adults and shows excellent test-
retest reliability. This presents the intriguing possibility 
that in-vivo measurements of brain volume could be 
used as an alternative ageing biomarker. 
It is well-known that ageing affects the brain, both in 
terms of outward behavioural changes and cognitive 
decline, alongside alterations to the brain’s biophysical 
structure and cellular and molecular functioning. Using 
measures of brain volume derived from T1-weighted 
structural MRI, assumed to reflect grey and white 
matter atrophy, high levels of age prediction accuracy 
have been consistently achieved. For example, our work 
found a mean/median absolute error of age prediction of 
4.2/3.4 years, with a correlation between age and brain-
predicted age of r = 0.96, R2 = 0.92 [3]. This  is compar- 
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able to or better than leading biological age prediction 
models, for example using DNA methylation status (r = 
0.96, median absolute error = 3.6 years) [4] or a panel 
of blood chemistry markers (r = 0.91, mean absolute 
error = 5.6 years) [2]. 
Given the excellent performance of neuroimaging-
derived age predictions, it is curious how brain volume 
has not been considered more widely as a candidate 
ageing biomarker. For example, neuroimaging is not 
mentioned in the recent review by Wagner and 
colleagues [1] nor in a collaboratively-developed 
proposed panel of ageing biomarkers [5]. Our data 
suggest that the addition of neuroimaging to the 
pantheon of candidate ageing biomarkers could be 
highly beneficial. When predicting time to mortality, 
arguably the ‘gold standard’ of health outcomes, we 
showed that neuroimaging-derived brain-age 
outperformed both DNA-methylation age and leukocyte 
telomere length [6]. In fact, telomere length was only 
related to survival at chance levels. Interestingly, when 
neuroimaging-derived brain-age and DNA-methylation 
age, themselves uncorrelated, were combined in 
statistical model to predict survival in older adults, the 
resulting model significantly outperformed a model 
containing each predictor individually. This suggests 
that biological ageing can potentially be 
compartmentalised, and that when premature ageing 
occurs in different compartments (e.g., haemo-
epigenetic, neurological), the risk of poor health 
outcomes is substantially increased. 
Given the published data on neuroimaging-derived 
brain-age, I believe it is worth considering it 
qualification against a set of consensus ageing 
biomarker criteria. Paraphrasing from the American 
Federation for Aging Research recommendations, an 
ageing biomarker must: 
1. Predict the rate of ageing (i.e., estimate where a 
person is in their total life span). 
2. Measure a basic process that underlies ageing, 
not the effects of disease.   
3. Be able to be tested repeatedly without causing 
harm. 
4. Work in humans and laboratory animals. 
Based on the above evidence regarding prediction of 
survival [6], I assert that neuroimaging-derived brain-
age meets criteria #1. Given the accuracy of age 
prediction [3] and the fact that brain atrophy occurs in 
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the context of non-pathological ageing, this satisfies 
criteria #2. As a non-invasive imaging technique, T1-
weighted MRI meets criteria #3. Finally, the accuracy 
of this technique in non-human primates has been 
recently reported [7], suggesting that it appropriately 
meets criteria #4. While perhaps the major caveat 
regarding the use of neuroimaging in this context is the 
cost and potential logistics, projects like the UK 
Biobank imaging study (http://imaging.ukbiobank. 
ac.uk/) show that collecting neuroimaging data on an 
extremely large scale (N = 100,000) are becoming 
increasingly feasible. It is timely for a marriage of 
neuroscience and biogerontology, and approaches that 
combine the most complementary information on the 
ageing human body will have the greatest utility in 
developing effective ageing biomarkers. 
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